结直肠癌肝转移组织病理学生长方式研究进展

doi:10.3760/cma.j.cn371439-20231016-00017

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (2): 114-118.doi: 10.3760/cma.j.cn371439-20231016-00017

结直肠癌肝转移组织病理学生长方式研究进展

孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹()

山东第一医科大学附属省立医院肿瘤微创科，济南 250021

收稿日期:2023-10-16 修回日期:2024-01-20 出版日期:2024-02-08 发布日期:2024-04-03
通讯作者: 沙丹，Email：shadan@sdfmu.edu.cn
基金资助:
山东省自然科学基金(ZR2021MH140);济南市临床医学科技创新计划(202019085)

Research progress on the histopathological growth patterns of colorectal liver metastasis

Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan()

Department of Minimally Invasive Treatment of Cancer，Shandong Provincial Hospital Affiliated to Shandong First Medical University，Jinan 250021，China

Received:2023-10-16 Revised:2024-01-20 Online:2024-02-08 Published:2024-04-03
Contact: Sha Dan，Email：shadan@sdfmu.edu.cn
Supported by:
Natural Science Foundation of Shandong Province of China(ZR2021MH140);Science and Technology Innovation Development Program of Jinan of Shandong Province(202019085)

摘要/Abstract

摘要：

结直肠癌（CRC）肝转移瘤的不同组织病理学生长方式（HGP）反映了肿瘤与宿主之间复杂而多变的相互作用。探讨HGP肿瘤血管化特点和免疫特征、HGP与抗肿瘤治疗疗效的关系以及HGP预测方法对于制定最佳治疗方案、评估患者预后和监测疾病进展具有潜在的临床应用价值。

关键词: 结直肠肿瘤, 肿瘤转移, 肝肿瘤, 组织病理学生长方式

Abstract:

The histopathological growth patterns （HGPs）of colorectal cancer （CRC）liver metastasis reflect the complicated and varied interactions between tumor cells and host microenvironment. Exploring the tumor vascular and immunological features of HGPs，the relationship between HGPs and anti-tumor treatment efficacy，and HGPs prediction methods may have potential clinical aplication value for making optimal treatment strategies，evaluating patients' prognosis，and monitoring disease progression.

Key words: Colorectal neoplasms, Neoplasm metastasis, Liver neoplasms, Histopathological growth patterns

孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.

Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.

参考文献 32

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Rahbari NN, Carr PR, Jansen L, et al. Time of metastasis and outcome in colorectal cancer[J]. Ann Surg, 2019, 269(3): 494-502. DOI: 10.1097/SLA.0000000000002564. pmid: 29064893
[3]	Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3): 233-254. DOI: 10.3322/caac.21772.
[4]	Wu Y, Mao A, Wang H, et al. Association of simultaneous vs delayed resection of liver metastasis with complications and survival among adults with colorectal cancer[J]. JAMA Netw Open, 2022, 5(9): e2231956. DOI: 10.1001/jamanetworkopen.2022.31956.
[5]	van Dam PJ, van der Stok EP, Teuwen LA, et al. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis[J]. Br J Cancer, 2017, 117(10): 1427-1441. DOI: 10.1038/bjc.2017.334.
[6]	Latacz E, Höppener D, Bohlok A, et al. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights[J]. Br J Cancer, 2022, 127(6): 988-1013. DOI: 10.1038/s41416-022-01859-7.
[7]	Vermeulen PB, Colpaert C, Salgado R, et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia[J]. J Pathol, 2001, 195(3): 336-342. DOI: 10.1002/path.966. pmid: 11673831
[8]	Stessels F, Van den Eynden G, Van der Auwera I, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia[J]. Br J Cancer, 2004, 90(7): 1429-1436. DOI: 10.1038/sj.bjc.6601727.
[9]	Galjart B, Nierop PMH, van der Stok EP, et al. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases[J]. Angiogenesis, 2019, 22(2): 355-368. DOI: 10.1007/s10456-019-09661-5. pmid: 30637550
[10]	Haas G, Fan S, Ghadimi M, et al. Different forms of tumor vascularization and their clinical implications focusing on vessel co-option in colorectal cancer liver metastases[J]. Front Cell Dev Biol, 2021, 9: 612774. DOI: 10.3389/fcell.2021.612774.
[11]	Frentzas S, Simoneau E, Bridgeman VL, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases[J]. Nat Med, 2016, 22(11): 1294-1302. DOI: 10.1038/nm.4197. pmid: 27748747
[12]	Latacz E, Caspani E, Barnhill R, et al. Pathological features of vessel co-option versus sprouting angiogenesis[J]. Angiogenesis, 2020, 23(1): 43-54. DOI: 10.1007/s10456-019-09690-0. pmid: 31655928
[13]	Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330. DOI: 10.1038/nature21349.
[14]	Stremitzer S, Vermeulen P, Graver S, et al. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases[J]. Br J Cancer, 2020, 122(10): 1518-1524. DOI: 10.1038/s41416-020-0812-z.
[15]	Höppener DJ, Nierop PMH, Hof J, et al. Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis[J]. Br J Cancer, 2020, 123(2): 196-206. DOI: 10.1038/s41416-020-0881-z.
[16]	Liang JY, Xi SY, Shao Q, et al. Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy[J]. Cancer Immunol Immunother, 2020, 69(12): 2623-2634. DOI: 10.1007/s00262-020-02632-6.
[17]	Garcia-Vicién G, Mezheyeuski A, Micke P, et al. Spatial immunology in liver metastases from colorectal carcinoma according to the histologic growth pattern[J]. Cancers (Basel), 2022, 14(3): 689. DOI: 10.3390/cancers14030689.
[18]	Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial[J]. Gut, 2022, 71(1): 34-42. DOI: 10.1136/gutjnl-2020-322339. pmid: 33384335
[19]	Yu J, Green MD, Li S, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination[J]. Nat Med, 2021, 27(1): 152-164. DOI: 10.1038/s41591-020-1131-x. pmid: 33398162
[20]	Höppener DJ, Nierop PMH, Herpel E, et al. Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy[J]. Clin Exp Metastasis, 2019, 36(4): 311-319. DOI: 10.1007/s10585-019-09975-0.
[21]	Buisman FE, van der Stok EP, Galjart B, et al. Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases[J]. Clin Exp Metastasis, 2020, 37(5): 593-605. DOI: 10.1007/s10585-020-10048-w.
[22]	Rigamonti A, Feuerhake F, Donadon M, et al. Histopathological and immune prognostic factors in colo-rectal liver metastases[J]. Cancers (Basel), 2021, 13(5): 1075. DOI: 10.3390/cancers13051075.
[23]	Höppener DJ, Galjart B, Nierop PMH, et al. Histopathological growth patterns and survival after resection of colorectal liver metastasis: an external validation study[J]. JNCI Cancer Spectr, 2021, 5(3): pkab026. DOI: 10.1093/jncics/pkab026.
[24]	Viganò L, Branciforte B, Laurenti V, et al. The histopathological growth pattern of colorectal liver metastases impacts local recurrence risk and the adequate width of the surgical margin[J]. Ann Surg Oncol, 2022, 29(9): 5515-5524. DOI: 10.1245/s10434-022-11717-8.
[25]	Nierop PMH, Galjart B, Höppener DJ, et al. Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns[J]. Clin Exp Metastasis, 2019, 36(2): 109-118. DOI: 10.1007/s10585-019-09960-7.
[26]	Wei M, Zhang Y, Yang X, et al. Claudin-2 promotes colorectal cancer growth and metastasis by suppressing NDRG1 transcription[J]. Clin Transl Med, 2021, 11(12): e667. DOI: 10.1002/ctm2.667. pmid: 34965023
[27]	Paquet-Fifield S, Koh SL, Cheng L, et al. Tight junction protein claudin-2 promotes self-renewal of human colorectal cancer stem-like cells[J]. Cancer Res, 2018, 78(11): 2925-2938. DOI: 10.1158/0008-5472.CAN-17-1869. pmid: 29510994
[28]	Wang YB, Shi Q, Li G, et al. MicroRNA-488 inhibits progression of colorectal cancer via inhibition of the mitogen-activated protein kinase pathway by targeting claudin-2[J]. Am J Physiol Cell Physiol, 2019, 316(1): C33-C47. DOI: 10.1152/ajpcell.00047.2018.
[29]	Tabariès S, Annis MG, Lazaris A, et al. Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern[J]. Commun Biol, 2021, 4(1): 657. DOI: 10.1038/s42003-021-02189-9. pmid: 34079064
[30]	Cheng J, Wei J, Tong T, et al. Prediction of histopathologic growth patterns of colorectal liver metastases with a noninvasive imaging method[J]. Ann Surg Oncol, 2019, 26(13): 4587-4598. DOI: 10.1245/s10434-019-07910-x. pmid: 31605342
[31]	Han Y, Chai F, Wei J, et al. Identification of predominant histopathological growth patterns of colorectal liver metastasis by multi-habitat and multi-sequence based radiomics analysis[J]. Front Oncol, 2020, 10: 1363. DOI: 10.3389/fonc.2020.01363. pmid: 32923388
[32]	Starmans MPA, Buisman FE, Renckens M, et al. Distinguishing pure histopathological growth patterns of colorectal liver metastases on CT using deep learning and radiomics: a pilot study[J]. Clin Exp Metastasis, 2021, 38(5): 483-494. DOI: 10.1007/s10585-021-10119-6.

结直肠癌肝转移组织病理学生长方式研究进展

Research progress on the histopathological growth patterns of colorectal liver metastasis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[4]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[7]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[8]	向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪. 脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519.
[9]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[10]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[11]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[12]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[13]	李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[14]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[15]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.